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Compared with bare-metal stents,drug-eluting stents (DES) havegreatly reduced the riskof in-stent restenosis(ISR) by inhibiting
neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events. Recently, stent fracture
(SF)hasemerged asapotential mechanismofDES failurethatisassociatedwith ISR. Stentfracture isstronglyrelated tostent type,
andprior reports suggest that deployment ofsirolimuseluting stents (SES) maybe associatedwith a higher risk of SF compared to
other DES. Everolimus eluting stents (EESs) represent a new generation of DES with promising results. The occurrence of SF with
EES has not been well established. The present paper describes two cases of EES fracture associated with ISR.
1.Introduction
The occurrence of stent fractures (SF) is recognized as a po-
tential complicationof stent deployment.Its incidencevaries
markedly in published reports, ranging from less than
1% to more than 16% [1–3]. Little is known about the
precise incidence of SF in the “real world”. However, SF is
likely to be underrecognized due to diﬃculty in diagnosis
and the lack of standardized deﬁnitions. Stent fracture has
currently become an important concern after drug-eluting
stent(DES)implantationduetoitspotentialassociationwith
in-stent restenosis (ISR)andstentthrombosis [4].Sirolimus-
eluting stents (SES), as compared with paclitaxel (PES) or
zotarolimus-eluting stents (ZES), are considered the DES
with the highest risk of SF [5, 6].
The everolimus eluting stent (EES; Multilink Vision
platform, Abbott Vascular, Temecula, CA), is a new DES
with promising long-term results [7–9]. As compared with
other DES, EES provides the thinnest available strut proﬁle
(0.08mm) [10]. The incidence of SF with EES has never
been assessed. The present paper describes two cases of EES
fracture associated with ISR.
2.Case Reports
2.1. Case-1. This patient was a 72-year-old lady with a chief
complaint of prolonged chest pain. Her medical history
included hypertension, hyperlipidemia, family history of
coronary artery disease, and cutaneouslupuserythematosus.
In May 2009, she experienced exertional chest pain and
underwent coronary angiography which revealed a calciﬁc
90% mid- and 80% distal RCA stenosis. The distal lesion
was treated with rotational atherectomy using 1.25mm
burr following which a 2.25 × 23mm Xience V stent
(Abbott Vascular Devices, Santa Clara, CA) was deployed
at 16 atmospheres (ATM). A 2.75 × 28mm Xience V stent
was then deployed at 16ATM in the mid-segment, and
postdilated with a 3.25 × 10mm noncompliant balloon
up to 24ATM. An excellent result was achieved, and she
was discharged home in a stable condition (Figure 1). Four
months later she presented to the emergency department
with a prolonged episode of chest pain associated with T
wave inversion in the inferior leads and an elevated troponin
I. Coronary angiography revealed focal in-stent restenosis
(ISR) in the mid-RCA (Figure 2(a)). Multiple ﬂuoroscopic2 Cardiology Research and Practice
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Figure 1: Angiographic images of the right coronary artery with a signiﬁcant mid-segment calciﬁed stenosis (a) and ﬁnal result after
deployment of a 2.75 × 28mm and 2.25 × 23mm Xience V stents (b).
(a)
(B1)
(b)
Figure 2: Focal in-stent restenosis of the mid-right coronary artery (a). Complete stent fracture with a clear separation of the stent struts
(b). Imaging of the Xience V stent conﬁrming no separation between struts at the original stent procedure (B1).
images revealed a gap in the middle of the EES stent indi-
cating a complete stent fracture (Figure 2(b)) probably
relatedtotheseverecalciﬁcationandangulationoftheartery.
We elected to cover this with a further stent. Predilation
was performed with a 2.5 × 15mm balloon at 18ATM and
a3 . 0× 13mm Cypher Select Plus stent was delivered at
24ATM,withanexcellentﬁnalresult.Nofurtherangiograms
were performed as the patient remained free of symptoms.
2.2. Case-2. This patient was a 67-year-old lady with recur-
rent chest pain associated with dyspnea. Her medical history
included former smoking, hypertension, hyperlipidemia,
diabetes mellitus, and chronic obstructive pulmonary dis-
ease. She underwent quadruple bypass surgery in 2004 with
a left internal thoracic artery (LITA) to the LAD and 3
venous grafts, to the RCA, diagonal, and obtuse marginal
arteries. She required a dual-chamber pacemaker 2 days
after bypass surgery. In July 2005, she developed stable class
III angina, and coronary angiography revealed a stenosis
where the LITA was inserted into the LAD. This was treated
with a bare metal stent (BMS). She was stable until June
2009 when she developed recurrent angina and was found
to have ISR within the BMS stent. On this occasion, we
elected to perform PCI and stenting of the native LAD
across the distal anastomosis of the LITA graft. A total
of three overlapping everolimus eluting stents (EESs) were
deployed. A 2.5 × 18mm and 2.5 × 25mm Xience V
stents and 2.25 × 15mm Promus stent (Boston Scientiﬁc
Corp., Natick, MA) were implanted from distal to proximal
with good angiographic results (Figure 3). Five months
later, she again presented with progressive angina. Repeat
coronary angiography demonstrated focal in-stent restenosis
in two stents (the 2.5 × 18mm Xience V and the 2.25 ×
15mm Promus). Further angiographic evaluation revealed
stent strut separation in the two stents at the focal ISR site
indicating a complete stent fracture (Figure 4). Predilatation
of both sites was performed with a 2.5 × 15mm balloon.
We deployed a 2.5 × 14mm Endeavor stent (Medtronic
CardioVascular, Santa Rosa, CA) covering the distal stent
fracture position at 18ATM. Considerable stent movement
was visible with each cardiac cycle. We felt that additional
stenting and structural support would be required for
success. Therefore a second Endeavor 3.0 × 30mm stent
was deployed to cover this segment, extending back throughCardiology Research and Practice 3
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Figure 3: Angiographic images of the left anterior descending artery after two Xience V and one Promus stent deployment showing the
absence of stent strut separation (a) and the presence of a good angiographic result (b).
(a) (b)
Figure 4: Focal in-stent restenosis of the mid- and distal left anterior descending artery (a). Double stent fracture with complete strut
separation in two diﬀerent locations (b).
the ISR in the mid-LAD. The mid-portion of the stented
segment was then postdilated with a 3.0 × 15mm non
compliant balloon to a maximum of 22ATM. An excellent
angiographic result was obtained (Figure 5). Subsequently,
she represented in July 2009 again with troponin-negative
progressive angina. Repeat coronary angiography revealed
that she had a fracture within her Endeavor 3.0 × 30mm
stent (Figure 6) and had developed occlusive ISR within her
LAD. On this occasion, she had repeat PCI to her LITA into
LAD with further deployment of an Endeavor 2.5 × 30mm
with a good angiographic result.
3.Discussion
Stent fracture, currently an important concern after DES
implantation,hasbeenassociated withahigherpotentialrisk
of ISR and stent thrombosis [4]. The mechanism of ISR in
stent fracture isprobablyrelated to lowerdrug delivery at the
fracturesiteandhighermechanicalirritationbythefractured
struts causing smooth muscle proliferation and impaired re-
endothelization [11].
Stent fracture has been linked to longer stent length,
stent overlap, stent overexpansion, lesion calciﬁcation,severe
angulationanddynamicﬂexure[5,12,13].Sirolimus-eluting
stent deployment is also considered a risk factor for SF
[5, 6]. Nonetheless, it remains unclear if the relatively high
incidence of SF is related to its strut structure, component
materials, the type of antiproliferative drug, or just because
it is underdetected as compared with other stents [6].
The risk of SF in EES has never been assessed, perhaps
due to the relatively new introduction of this stent. EES
uses cobalt chromium technology and confers a very unique
architecture with the thinnest strut proﬁle [10]. It remains
unknown if this design and the cobalt chromium composi-
tion might modify the risk of SF compared to the stainless
steel DES generation (SES and PES). In our case reports,
SF was associated with a focal ISR pattern, which is very
frequently seen with SES fractures [14] .T h ef r a c t u r es i t e s
were all at hinge movement points that occur in areas of
curves and twists leading to increased shear forces on the
vessel wall and stent. The repetitive cardiac contractions may
ultimately lead to metal fatigue and fracture. Both patients4 Cardiology Research and Practice
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Figure 5: Angiographic images of the left anterior descending artery after two Endeavor stents deployment showing the absence of stent
strut separation (a) and the presence of a good angiographicresult (b).
Figure 6: Complete Endeavor stent fracture of the distal left ante-
rior descending coronary artery.
presentedwithanacutecoronarysyndrome secondarytoISR
without evidence of stent thrombosis.
The treatment of SF is a challenging situation due to the
absence of formal recommendations. In our cases, we used
ad i ﬀerent stent platform and polymer coating to treat the
stent fractures. In the ﬁrst case, we used an SES, and for the
secondcase,azotarolimuselutingstent.AlthoughSFappears
to be more frequent after SES than other DES implantation,
in lesions with high angulations, especially those in the right
coronary artery, SF can occur in any type of stent. While
no clinical trials have showed any advantage in changing
the type of DES, this strategy has never been evaluated
speciﬁcally in patients with SF.
In conclusion, this report illustrates two cases of EES
restenosis secondary to stent fracture. Further studies should
be performed to clarify whether this is an important issue or
a sporadic observation.
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